Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 2:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2353–2376 of 7,881 matching trials from the live ClinicalTrials.gov search.
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
MEDI-551 2 mg/kg, Rituximab, ICE, DHAP, Autologous Stem Cell Transplant (ASCT), MEDI-551 4 mg/kg
Drug · Procedure
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
29
States / cities
Birmingham, Alabama • Burbank, California • Palm Springs, California + 25 more
Conditions
HIV Infections
Interventions
Alendronate, Calcium carbonate, Vitamin D
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
25 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
28
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 17 more
Conditions
Gastrointestinal Stromal Tumors
Interventions
DCC-2618, Placebo Oral Tablet
Drug
Lead sponsor
Deciphera Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
15
States / cities
Scottsdale, Arizona • Los Angeles, California • Stanford, California + 10 more
Conditions
Recurrent B Acute Lymphoblastic Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Mitoxantrone, Mitoxantrone Hydrochloride, Pegaspargase, Pharmacological Study, Radiation Therapy, Therapeutic Hydrocortisone, Thioguanine, Vincristine, Vincristine Sulfate
Procedure · Drug · Biological + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 31 Years
Enrollment
669 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
166
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 135 more
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Canakinumab, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years to 80 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
11
States / cities
Anaheim, California • Los Angeles, California • Panama City, Florida + 8 more
Conditions
Diabetes Mellitus, Type 1
Interventions
Insulin lispro, recombinant human hyaluronidase PH20, Insulin aspart, Insulin glulisine, Insulin glargine
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
19
States / cities
Escondido, California • La Jolla, California • San Mateo, California + 16 more
Conditions
DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma, Refractory Multiple Myeloma, Smoldering Multiple Myeloma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Laboratory Biomarker Analysis, Lenalidomide, Melphalan, Peripheral Blood Stem Cell Transplantation, Placebo Administration
Procedure · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2027
U.S. locations
140
States / cities
Scottsdale, Arizona • Duarte, California • Sacramento, California + 103 more
Conditions
Epidermolysis Bullosa
Interventions
SD-101-6.0 cream
Drug
Lead sponsor
Scioderm, Inc.
Industry
Eligibility
1 Month and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
15
States / cities
Phoenix, Arizona • Redwood City, California • Aurora, Colorado + 12 more
Conditions
Glioblastoma Multiforme, Anaplastic Astrocytoma
Interventions
Toca 511, Toca FC, Lomustine, Temozolomide, Bevacizumab
Biological · Drug
Lead sponsor
Tocagen Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
50
States / cities
Phoenix, Arizona • Irvine, California • La Jolla, California + 41 more
Conditions
AVB - Atrioventricular Block, Fetal AVB
Interventions
Dexamethasone, IVIG
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Enrollment
1,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 17 more
Withdrawn Not applicable Interventional Accepts healthy volunteers

Rapid Diagnostics for HIV and Hepatitis

NCT02190305
Conditions
HIV Infections, Hepatitis B Infections, Hepatitis C Infections
Interventions
Multiplo HBc/HIV/HCV and Reveal HBsAg
Device
Lead sponsor
MedMira Laboratories Inc.
Industry
Eligibility
13 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
4
States / cities
Los Angeles, California • Miami, Florida • Minneapolis, Minnesota + 1 more
Completed Phase 1Phase 2 Interventional Results available

ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma

NCT01592045
Conditions
Neuroblastoma
Interventions
ch14.18 -NCI, ch14.18-UTC, Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), Aldesleukin (IL-2), Isotretinoin
Biological · Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
Up to 8 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 10 more
Conditions
Peripheral Artery Disease
Interventions
intermittent pneumatic compression, exercise, Sham device, Health Education
Device · Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
55 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
4
States / cities
Chicago, Illinois • Detroit, Michigan • Minneapolis, Minnesota
Conditions
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Interventions
LY3537982, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
87
States / cities
Huntsville, Alabama • Gilbert, Arizona • Phoenix, Arizona + 72 more
Conditions
Seasonal Allergic Rhinitis, SAR
Interventions
BDP HFA, Placebo nasal aerosol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
715 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
45
States / cities
Oxford, Alabama • Bell, California • Costa Mesa, California + 40 more
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
filgrastim, sargramostim, cytarabine, daunorubicin hydrochloride, zosuquidar trihydrochloride, Placebo
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
60 Years and older
Enrollment
449 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
91
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 67 more
Conditions
Coronary Artery Disease
Interventions
PROMUS Element Coronary Stent System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
14
States / cities
Bakersfield, California • Ocala, Florida • Orlando, Florida + 11 more
Conditions
Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
Actelion
Industry
Eligibility
3 Months and older
Enrollment
3,515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
54
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 39 more
Conditions
Ganglioneuroblastoma, Stage 1 Neuroblastoma, Stage 2 Neuroblastoma, Stage 2A Neuroblastoma, Stage 2B Neuroblastoma, Stage 3 Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Cisplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, External Beam Radiation Therapy, Filgrastim, Laboratory Biomarker Analysis, Melphalan, Mesna, Peripheral Blood Stem Cell Transplantation, Pharmacological Study, Topotecan Hydrochloride, Vincristine Sulfate
Procedure · Drug · Radiation + 2 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
113
States / cities
Birmingham, Alabama • Downey, California • Duarte, California + 90 more
Terminated Phase 3 Interventional Results available

A Study of Evacetrapib in High-Risk Vascular Disease

NCT01687998
Conditions
Cardiovascular Diseases
Interventions
Evacetrapib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
12,092 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
176
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 173 more
Conditions
Anemia, Fatigue, Prostate Cancer
Interventions
epoetin alfa, dexamethasone
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years · Male only
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
140
States / cities
Modesto, California • Aurora, Colorado • Boulder, Colorado + 92 more
Completed Phase 4 Interventional Accepts healthy volunteers

Aldara for the Treatment of Extensive Alopecia Areata

NCT00177021
Conditions
Alopecia Areata
Interventions
Aldara Cream 5%
Drug
Lead sponsor
Hordinsky, Maria K., MD
Individual
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2002
U.S. locations
1
States / cities
Minneapolis, Minnesota
Completed No phase listed Observational Accepts healthy volunteers

DPBRN Patient Satisfaction With Dental Restorations

NCT01201421
Conditions
Patient Satisfaction
Interventions
Not listed
Lead sponsor
Dental Practice-Based Research Network
Network
Eligibility
13 Years and older
Enrollment
5,932 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
6
States / cities
Birmingham, Alabama • Gainesville, Florida • Minneapolis, Minnesota + 1 more
Conditions
Urinary Catheterization, Urinary Tract Infections
Interventions
Truvalve, Control (catheter drainage bag)
Device · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
2
States / cities
Edina, Minnesota • Minneapolis, Minnesota